Literature DB >> 22864805

The chronic gastrointestinal consequences associated with campylobacter.

Mark S Riddle1, Ramiro L Gutierrez, Elena F Verdu, Chad K Porter.   

Abstract

Campylobacteriosis is a leading cause of acute infectious diarrhea in the developing world, where it causes considerable mortality, and in developed countries, where it accounts for significant healthcare and other costs. Evidence has emerged from basic science, clinical, and epidemiological domains that suggests that Campylobacter infection is not limited to acute illness but is also involved in the development of well-described extraintestinal sequelae, such as the Guillain-Barré syndrome and reactive arthritis, and may also contribute to the pathogenesis of chronic gastrointestinal conditions. This review will focus on the role of Campylobacter infection as a risk factor for the development of chronic gastrointestinal sequelae, such as functional gastrointestinal disorders, with which irritable bowel syndrome has been most frequently associated, inflammatory bowel disease, and celiac disease.

Entities:  

Mesh:

Year:  2012        PMID: 22864805     DOI: 10.1007/s11894-012-0278-0

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  93 in total

Review 1.  Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease.

Authors:  W Clark; J Raftery; F Song; P Barton; C Cummins; A Fry-Smith; A Burls
Journal:  Health Technol Assess       Date:  2003       Impact factor: 4.014

Review 2.  Sources of Campylobacter colonization in broiler chickens.

Authors:  D G Newell; C Fearnley
Journal:  Appl Environ Microbiol       Date:  2003-08       Impact factor: 4.792

3.  Campylobacteriosis rates show age-related static bimodal and seasonality trends.

Authors:  Warrick Nelson; Ben Harris
Journal:  N Z Med J       Date:  2011-06-24

4.  Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis.

Authors:  Alexandra-Chloé Villani; Mathieu Lemire; Marroon Thabane; Alexandre Belisle; Geneviève Geneau; Amit X Garg; William F Clark; Paul Moayyedi; Stephen M Collins; Denis Franchimont; John K Marshall
Journal:  Gastroenterology       Date:  2010-01-04       Impact factor: 22.682

5.  Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, case-control study.

Authors:  Sally D Parry; Rosamund Stansfield; Diana Jelley; Wendy Gregory; Elizabeth Phillips; J Roger Barton; Mark R Welfare
Journal:  Am J Gastroenterol       Date:  2003-09       Impact factor: 10.864

6.  Is irritable bowel syndrome more common in patients presenting with bacterial gastroenteritis? A community-based, case-control study.

Authors:  Sally D Parry; Rosamund Stansfield; Diana Jelley; Wendy Gregory; Elizabeth Phillips; J Roger Barton; Mark R Welfare
Journal:  Am J Gastroenterol       Date:  2003-02       Impact factor: 10.864

7.  Post-infectious functional gastrointestinal disorders in children.

Authors:  Miguel Saps; Licia Pensabene; Lucio Di Martino; Annamaria Staiano; Joshua Wechsler; Xiaotian Zheng; Carlo Di Lorenzo
Journal:  J Pediatr       Date:  2008-02-14       Impact factor: 4.406

8.  Infectious gastroenteritis and risk of developing inflammatory bowel disease.

Authors:  Chad K Porter; David R Tribble; Pablo A Aliaga; Heather A Halvorson; Mark S Riddle
Journal:  Gastroenterology       Date:  2008-06-05       Impact factor: 22.682

9.  Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine.

Authors:  Anne Prenzler; Linnette Yen; Thomas Mittendorf; J-Matthias von der Schulenburg
Journal:  BMC Health Serv Res       Date:  2011-07-05       Impact factor: 2.655

10.  Gnotobiotic IL-10; NF-kappaB mice develop rapid and severe colitis following Campylobacter jejuni infection.

Authors:  Elisabeth Lippert; Thomas Karrasch; Xiaolun Sun; Brigitte Allard; Hans H Herfarth; Deborah Threadgill; Christian Jobin
Journal:  PLoS One       Date:  2009-10-20       Impact factor: 3.240

View more
  23 in total

1.  Risks for celiac disease: bacteria make it three.

Authors:  J I Keenan; A S Day
Journal:  Dig Dis Sci       Date:  2013-11       Impact factor: 3.199

2.  Impact of rurality, broiler operations, and community socioeconomic factors on the risk of campylobacteriosis in Maryland.

Authors:  Barbara Zappe Pasturel; Raul Cruz-Cano; Rachel E Rosenberg Goldstein; Amanda Palmer; David Blythe; Patricia Ryan; Brenna Hogan; Carrianne Jung; Sam W Joseph; Min Qi Wang; Mei-Ling Ting Lee; Robin Puett; Amy R Sapkota
Journal:  Am J Public Health       Date:  2013-10-17       Impact factor: 9.308

Review 3.  Economics and financing of vaccines for diarrheal diseases.

Authors:  Sarah M Bartsch; Bruce Y Lee
Journal:  Hum Vaccin Immunother       Date:  2014-04-22       Impact factor: 3.452

Review 4.  Global Epidemiology of Campylobacter Infection.

Authors:  Nadeem O Kaakoush; Natalia Castaño-Rodríguez; Hazel M Mitchell; Si Ming Man
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 5.  A capsule conjugate vaccine approach to prevent diarrheal disease caused by Campylobacter jejuni.

Authors:  Alexander C Maue; Frédéric Poly; Patricia Guerry
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

Review 6.  The microbiota-gut-brain axis in functional gastrointestinal disorders.

Authors:  Giada De Palma; Stephen M Collins; Premysl Bercik
Journal:  Gut Microbes       Date:  2014-06-12

Review 7.  Controlled Human Infection Models To Accelerate Vaccine Development.

Authors:  Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores
Journal:  Clin Microbiol Rev       Date:  2022-07-06       Impact factor: 50.129

Review 8.  The Role of the Microbiota in Shaping Infectious Immunity.

Authors:  Timothy W Hand
Journal:  Trends Immunol       Date:  2016-09-05       Impact factor: 16.687

9.  The RNase R from Campylobacter jejuni has unique features and is involved in the first steps of infection.

Authors:  Nabila Haddad; Rute G Matos; Teresa Pinto; Pauline Rannou; Jean-Michel Cappelier; Hervé Prévost; Cecília M Arraiano
Journal:  J Biol Chem       Date:  2014-08-06       Impact factor: 5.157

10.  Lack of homologous protection against Campylobacter jejuni CG8421 in a human challenge model.

Authors:  Beth D Kirkpatrick; Caroline E Lyon; Chad K Porter; Alex C Maue; Patricia Guerry; Kristen K Pierce; Marya P Carmolli; Mark S Riddle; Catherine J Larsson; Douglas Hawk; Elizabeth A Dill; A Fingar; Frederic Poly; Kelly A Fimlaid; Fahmida Hoq; David R Tribble
Journal:  Clin Infect Dis       Date:  2013-07-09       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.